

Department of Defense Tuberous Sclerosis Complex Research Program Funded Grants FY2002-2025

| State/Country | PI | Institution | Project | Award Total |
|-------------------|---------------------|---|--|------------------------|
| Arizona | | | | \$1,514,188.00 |
| 2019 | BOERWINKLE, VARINA | CHILDREN'S HOSPITAL, PHOENIX | Resting State Functional MRI Finds Correct Surgical Target to Stop Seizures in Tuberous Sclerosis Complex | \$746,999.00 |
| 2016 | NARAYANAN, VINODH | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) | Phenotypic Variability in Tuberous Sclerosis Complex (TSC) | \$767,189.00 |
| California | | | | \$10,511,628.00 |
| 2023 | RAJARAMAN, RAJSEKAR | UNIVERSITY OF CALIFORNIA, LOS ANGELES | Computational EEG Analysis to Predict Infantile Spasms Emergence, Treatment Response, and Relapse Among Children with Tuberous Sclerosis Complex | \$721,235.00 |
| 2021 | MCDONALD, NICOLE M | UNIVERSITY OF CALIFORNIA, LOS ANGELES | Assessment and Treatment of Behavior Problems in TSC at Preschool Age: A Telehealth Approach | \$1,167,408.00 |
| 2021 | DIAZ, BEGONA | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | Investigating Novel Targetable Vulnerabilities of LAM Disease | \$231,150.00 |
| 2020 | LEE, GINA | CALIFORNIA, UNIVERSITY OF, IRVINE | Mechanistic Understanding of m6A Signaling for the Treatment of TSC and LAM | \$706,500.00 |
| 2019 | KASARI, CONNIE | CALIFORNIA, UNIVERSITY OF, LOS ANGELES | TSC Remote Assessment and Intervention (TRAIN) | \$922,647.00 |
| 2018 | TZANNIS, STELIOS | DELOS PHARMACEUTICALS, INC. | Development of Novel, Highly mTORC1 Selective Inhibitors for the Treatment of Tuberous Sclerosis | \$472,028.00 |
| 2016 | SHI, WEI | CHILDREN'S HOSPITAL LOS ANGELES | Mechanisms of Pulmonary Lesions in TSC LAM | \$749,250.00 |
| 2015 | RUBENSTEIN, JOHN L | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | Functional Impact of TSC1 Mutations on the Development and Maturation of Inhibitory Cortical Neurons | \$950,181.00 |
| 2014 | JESTE, SHAFALI S | UNIVERSITY OF CALIFORNIA, LOS ANGELES | Early Behavioral Intervention to Improve Social Communication Function in Infants with TSC | \$267,508.00 |
| 2012 | GUAN, KUN-LIANG | UNIVERSITY OF CALIFORNIA, SAN DIEGO | Crosstalk between mTORC1 and cAMP Signaling | \$658,750.00 |
| 2012 | LIPTON, STUART A | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, LA JOLLA | Application of FDA-Approved Memantine and Newer NitroMemantine Derivatives to Treat Neurological Manifestations in Rodent Models of Tuberous Sclerosis Complex | \$195,000.00 |
| 2012 | SHAW, RUEBEN | SALK INSTITUTE | Defining the Role of Autophagy Kinase ULK1 Signaling in Therapeutic Response of Tuberous Sclerosis Complex to mTOR Inhibitors | \$816,000.00 |
| 2008 | GUAN, KUN-LIANG | UNIVERSITY OF CALIFORNIA, SAN DIEGO | Regulation of mTOR by Nutrients | \$675,002.00 |
| 2006 | KRIEGSTEIN, ARNOLD | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | The Role of Tuberin and Hamartin in Cortical Neuron Migration | \$616,467.00 |
| 2006 | SCHAFFER, DAVID | UNIVERSITY OF CALIFORNIA, BERKELEY | Tuberous Sclerosis Signaling in Adult Neurogenesis | \$101,840.00 |
| 2005 | BARABAN, SCOTT C | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | A Morpholino Strategy to Assess TSC Gene Function in Zebrafish | \$99,999.00 |
| 2005 | BOSS, GERRY R | UNIVERSITY OF CALIFORNIA, SAN DIEGO | Development of an Assay to Measure the Activation State of Rheb, the Downstream Target of TSC1/2, in Animal and Human Cells and Tissue | \$224,000.00 |
| 2005 | STOKOE, DAVID | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | Identification of Translationally Regulated mRNAs and UTR Sequences by TSC1 and TSC2 | \$100,000.00 |

Department of Defense Tuberous Sclerosis Complex Research Program Funded Grants FY2002-2025

| State/Country | PI | Institution | Project | Award Total |
|-----------------------------|----------------------|---|---|-----------------------|
| 2004 | TAMANOI, FUYUHIKO | UNIVERSITY OF CALIFORNIA, LOS ANGELES | A Genetic Approach to Define the Importance of Rheb in Tuberous Sclerosis | \$411,672.00 |
| 2003 | STOKOE, DAVID | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | The Role of GSK3 in Regulating Hamartin Phosphorylation and Activity in Response to Nutrients and Growth Factors | \$424,991.00 |
| Colorado | | | | \$237,967.00 |
| 2009 | SU, TIN TIN | UNIVERSITY OF COLORADO, BOULDER | Identification of Small Molecule Suppressors of Tsc Mutant Phenotypes in Drosophila | \$141,737.00 |
| 2005 | SU, TIN TIN | UNIVERSITY OF COLORADO, BOULDER | Drosophila as a 3-D Model System to Screen for Anti-Tuberous Sclerosis Therapeutics | \$96,230.00 |
| Connecticut | | | | \$2,727,571.00 |
| 2024 | MCCOOL, MASON | YALE UNIVERSITY | Regulation of Tuberous Sclerosis Complex Function by the Neurodevelopmental Disorder Risk Gene TRIO | \$335,000.00 |
| 2019 | BORDEY, ANGELIQUE | YALE UNIVERSITY | Exosome Contribution to Social Deficits in TSC | \$752,681.00 |
| 2015 | BORDEY, ANGELIQUE | YALE UNIVERSITY | Epilepsy Causes and Treatment in TSC | \$697,777.00 |
| 2009 | BORDEY, ANGELIQUE | YALE UNIVERSITY | Understanding the Etiology of Tuberous Sclerosis Complex | \$734,763.00 |
| 2006 | SUN, ZHAOXIA | YALE UNIVERSITY | TSC1 and the Cilium in Zebrafish Kidney Development | \$110,550.00 |
| 2004 | SQUILLACE, RACHEL M | THE ROTHBERG INSTITUTE FOR CHILDHOOD DISEASES | Generation of in Vitro Cellular Models of Lymphangioleiomyomatosis for the Development of Tuberous Sclerosis Therapeutics | \$96,800.00 |
| District of Columbia | | | | \$273,001.00 |
| 2022 | TORII, MASAOKI | CHILDREN'S RESEARCH INSTITUTE AT CNMC | Treatment of Epilepsy in Tuberous Sclerosis Complex by Interneuron Progenitor Transplantation | \$273,001.00 |
| Georgia | | | | \$695,969.00 |
| 2018 | WEN, ZHEXING | EMORY UNIVERSITY | Modeling TSC and Translating for Therapeutics with Human Cerebral Organoids | \$695,969.00 |
| Illinois | | | | \$2,584,655.17 |
| 2022 | AUERBACH, BENJAMIN D | ILLINOIS, UNIVERSITY OF, CHAMPAIGN/URBANA | Using Sensory Processing to Identify Neural Circuit Deficits and Novel Treatment Strategies in a Rat Model of TSC | \$237,899.00 |
| 2020 | YOSHII, AKIRA | ILLINOIS, UNIVERSITY OF, AT CHICAGO | Developing a Novel Therapy for Neurological Symptoms of Tuberous Sclerosis Complex | \$714,620.00 |
| 2017 | LE POOLE, ISABELLE | NORTHWESTERN UNIVERSITY | Toward Chimeric Antigen Receptor Transgenic T Cell Therapy for Tuberous Sclerosis Complex | \$720,118.17 |
| 2011 | LE POOLE, ISABELLE | LOYOLA UNIVERISTY CHICAGO | Developing Immunotherapeutic Options for TSC | \$797,643.00 |
| 2008 | WEI, JIAN-JUN | NORTHWESTERN UNIVERSITY | Repression of TSC2 Expression by miR-296 in Human Normal and Tumor Tissues | \$114,375.00 |
| Indiana | | | | \$964,386.00 |
| 2010 | QUILLIAM, LAWRENCE A | INDIANA UNIVERSITY, INDIANAPOLIS | Targeting ER Stress to Treat TSC | \$689,386.00 |
| 2004 | CASTRO, ARIEL F | INDIANA UNIVERSITY | Functional Relevance of the Ras-Related GTPase Rheb in Tuberous Sclerosis | \$275,000.00 |
| Iowa | | | | \$861,315.00 |
| 2023 | HARSHMAN, LYNDASAY | UNIVERISTY OF IOWA | Women's Health in Tuberous Sclerosis Complex: A Population-Based Assessment of Morbidity to Inform Clinical Care | \$748,815.00 |
| 2008 | HOHL, RAYMOND J | UNIVERISTY OF IOWA | Potential Contribution of the FOXO-Regulated Cell Cycle Inhibitor, Cyclin G2, to Growth Control in Tuberous Sclerosis | \$112,500.00 |
| Maryland | | | | \$3,026,666.00 |
| 2021 | LOTAN, TAMARA | JOHNS HOPKINS UNIVERSITY | Exploring and Leveraging Therapeutic Vulnerabilities in Renal Tumors with TSC1/2 Loss | \$818,750.00 |
| 2019 | LIN, DORIS DA MAY | JOHNS HOPKINS UNIVERSITY | Mapping of Brain GABA Levels in Tuberous Sclerosis Complex Using High-Resolution Proton MR Spectroscopic Imaging | \$897,716.00 |

Department of Defense Tuberous Sclerosis Complex Research Program Funded Grants FY2002-2025

| State/Country | PI | Institution | Project | Award Total |
|---------------------------|------------------------|--|--|------------------------|
| 2018 | ASRANI, KAUSHAL | JOHNS HOPKINS UNIVERSITY | mTORC1 Regulates MiTF Expression and Lysosomal Biogenesis | \$163,750.00 |
| 2011 | LOTAN, TAMARA | JOHNS HOPKINS UNIVERSITY | Role of TSC1/2 and mTOR Signaling in Epidermal Cell Differentiation | \$162,000.00 |
| 2008 | DARLING, THOMAS N | UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES/HENRY M. JACKSON FOUNDATION | Targeting Angiogenesis and Lymphangiogenesis in Tuberous Sclerosis Complex | \$684,450.00 |
| 2005 | XIAO, BO | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | Aberrant Glutamate Signaling and Tumor-Like Growth of Astrocytes in TSC | \$100,000.00 |
| Maryland continued | | | | |
| 2005 | XIAO, BO | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | Rheb in the Pathogenesis of Seizures in TSC | \$100,000.00 |
| 2004 | XIAO, BO | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | Driving the Formation of Tuberous Sclerosis Complex by Creating Conditional Rheb Transgenic Mice | \$100,000.00 |
| Massachusetts | | | | \$29,391,722.00 |
| 2024 | PRIOLO, CARMEN | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Role of the Glycome in TSC Biomarker Identification and Molecular Pathogenesis | \$1,683,194.00 |
| 2024 | TANG, YAN | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Mechanisms of Immune Suppression in TSC | \$266,368.00 |
| 2024 | PERRIMON, NORBERT | HARVARD UNIVERSITY | Regulation of Steroid Hormone Signaling and Lipid Metabolism by the Tuberous Sclerosis Complex | \$254,233.00 |
| 2023 | SHEN, JIE | BRIGHAM AND WOMEN'S HOSPITAL, INC. | A Novel Translational Mechanism Underlying TSC Pathophysiology | \$793,572.00 |
| 2023 | HENSKE, ELIZABETH | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Efficacy of Novel B7-H3 Antibodies in TSC | \$236,072.00 |
| 2023 | TANG, YAN | BRIGHAM AND WOMEN'S HOSPITAL, INC. | LAM-Targeting Nanoparticle-Assisted and Base Editor-Enabled Gene Therapy for Lymphangiomeiomyomatosis | \$263,598.00 |
| 2022 | PRIOLO, CARMEN | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Targeting Mitochondrial Metabolism in Tuberous Sclerosis Complex | \$855,709.00 |
| 2022 | ALESI, NICOLA | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Role of the Secreted Factor CTHRC1 in the Pathogenesis of TSC | \$253,636.00 |
| 2022 | BREAKEYFIELD, XANDRA O | MASSACHUSETTS GENERAL HOSPITAL | Can EVs Expand the Therapeutic Effect of Gene Replacement for Tsc1 in Brain? | \$726,382.00 |
| 2021 | KWIATKOWSKI, DAVID | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Targeting TSC by mTORC1-Specific Bi-Steric Inhibitors | \$857,947.00 |
| 2021 | TANG, YAN | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Tumor-Targeting Lipid Nanoparticle-Based siRNA Therapy for TSC | \$249,670.00 |
| 2020 | SAHIN, MUSTAFA | CHILDREN'S HOSPITAL, BOSTON | The Contribution of Rapamycin-Insensitive Processes to Neurological Symptoms in TSC | \$796,500.00 |
| 2020 | WEISSMAN, JONATHAN | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | Toward Pharmacological Rescue of TSC Loss of Function | \$292,500.00 |
| 2020 | LIU, HENG-JIA | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Therapeutic Targeting of the Immune Checkpoint Molecule B7-H3 in TSC | \$260,892.00 |
| 2019 | KWIATKOWSKI, DAVID | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Targeting mTOR/JUN/AXL Axis in TSC Tumors | \$262,652.00 |
| 2018 | TANG, YAN | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Dissecting Mechanisms of Immune Suppression in Tuberous Sclerosis Complex (TSC) by Integrative Single Cell Profiling of Tumor-Microenvironment Interaction | \$179,000.00 |
| 2018 | EL-CHEMALY, SOUHEIL | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Targeting the Angiotensin Receptor in TSC | \$748,620.00 |

Department of Defense Tuberous Sclerosis Complex Research Program Funded Grants FY2002-2025

| State/Country | PI | Institution | Project | Award Total |
|--------------------------------|-----------------------|------------------------------------|--|----------------|
| 2017 | LIPTON, JONATHAN | CHILDREN'S HOSPITAL, BOSTON | Targeting Circadian Clock Proteostasis as a Novel Therapeutic Strategy in Tuberous Sclerosis Complex | \$796,500.00 |
| 2017 | MANNING, BRENDAN | HARVARD UNIVERSITY | Mapping the Routes to Tumor Cell Death in TSC | \$717,750.00 |
| 2017 | PERRIMON, NORBERT | HARVARD UNIVERSITY | An Evolutionary Approach to Vulnerability Mapping in Order to Identify Alternative and Synergistic Therapeutic Strategies for TSC and Related Diseases | \$739,125.00 |
| 2017 | ZAREI, MAHSA | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Targeting Transcriptional Addiction for the Treatment of TSC | \$222,751.00 |
| 2016 | BELAID, AMINE | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Targeting Folate-Dependent Metabolic Pathways for the Treatment of TSC | \$253,850.00 |
| 2016 | EL-CHEMALY, SOUHEIL | BRIGHAM AND WOMEN'S HOSPITAL, INC. | LAMP: The LAM Microbiome Project | \$235,000.00 |
| 2016 | FELDMAN, ADAM S | MASSACHUSETTS GENERAL HOSPITAL | Evaluation of Lipid Poor Renal Masses with Magnetic Resonance Spectroscopy in Tuberous Sclerosis Complex | \$342,000.00 |
| 2016 | HENSKE, ELIZABETH | BRIGHAM AND WOMEN'S HOSPITAL, INC. | T Cell Dysfunction in TSC: Mechanisms and Targeted Therapy | \$628,989.00 |
| 2016 | GOLDBERG, MARCIA B | MASSACHUSETTS GENERAL HOSPITAL | Toward Novel Therapeutics for TSC and LAM: Using Mechanisms of a Bacterial Protein to Sensitize Cells to Rapamycin | \$327,437.00 |
| Massachusetts continued | | | | |
| 2016 | GIANNIKOU, KRINIO | BRIGHAM AND WOMEN'S HOSPITAL, INC. | Epigenetic Analysis of TSC Tumors to Identify Novel Therapeutic Targets | \$266,250.00 |
| 2015 | BREAKEFIELD, XANDRA O | MASSACHUSETTS GENERAL HOSPITAL | Systemic Gene Therapy for Tuberous Sclerosis | \$240,037.00 |
| 2015 | HOUSDEN, BENJAMIN | HARVARD UNIVERSITY | A Unique Opportunity for TSC: Repurposing FDA-Approved Drugs Using a Unique Combinatorial Screening Strategy | \$254,048.00 |
| 2015 | PRIOLO, CARMEN | BRIGHAM AND WOMEN'S HOSPITAL | Novel Metabolic Biomarkers in Tuberous Sclerosis Complex | \$250,633.00 |
| 2015 | ZHANG, WEI | JUVOBIO PHARMACEUTICALS INC. | Human-Induced Pluripotent TSC1 and TSC2 Mutant Stem Cell-Derived Neuronal Assays for Mechanistic Studies and Therapeutics Development | \$164,998.00 |
| 2014 | HENSKE, ELIZABETH P | BRIGHAM AND WOMEN'S HOSPITAL | Role of MicroRNA in the Pathogenesis and Treatment of TSC | \$803,679.00 |
| 2014 | KWIATKOWSKI, DAVID J | BRIGHAM AND WOMEN'S HOSPITAL | COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC | \$344,582.00 |
| 2014 | HENSKE, ELIZABETH P | BRIGHAM AND WOMEN'S HOSPITAL | Catalyzing Translational TSC Research: Novel LAM and AML Cell Culture Models | \$177,375.00 |
| 2014 | RAMESH, VIJAYA | MASSACHUSETTS GENERAL HOSPITAL | Patient-Specific Human iPSCs for Modeling TSC Pathophysiology and Therapeutic Discovery | \$1,000,450.00 |
| 2014 | SAHIN, MUSTAFA | CHILDREN'S HOSPITAL, BOSTON | Understanding the Role of TSC1/2 in Cerebellar Purkinje Neurons | \$717,951.00 |
| 2013 | EL-CHEMALY, SOUHEIL Y | BRIGHAM AND WOMEN'S HOSPITAL | Critical Roles for SYK in Lymphangiogenesis in LAM | \$162,318.00 |
| 2012 | BREAKFIELD, XANDRA O | BRIGHAM AND WOMEN'S HOSPITAL | Gene Therapy to Extend Lifespan of Tsc1 Conditional Brain Knockouts | \$158,297.00 |
| 2012 | HENSKE, ELIZABETH | BRIGHAM AND WOMEN'S HOSPITAL | Dysregulation of Cellular Metabolism: Novel Therapeutic Opportunities for TSC | \$905,089.00 |
| 2012 | PRIOLO, CARMEN | BRIGHAM AND WOMEN'S HOSPITAL | Novel Application for 18F-Fluorocholine PET Imaging in TSC | \$170,609.00 |
| 2012 | SAHIN, MUSTAFA | BOSTON CHILDREN'S HOSPITAL | Role of CTGF in White Matter Development in Tuberous Sclerosis | \$739,505.00 |
| 2011 | HENSKE, ELIZABETH | BRIGHAM AND WOMEN'S HOSPITAL | TSC1 and TSC2 Gene Homologs in Schizosaccharomyces Pombe | \$1,678,542.00 |

Department of Defense Tuberous Sclerosis Complex Research Program Funded Grants FY2002-2025

| State/Country | PI | Institution | Project | Award Total |
|--------------------------------|--------------------|--|--|-----------------------|
| 2011 | YU, JANE | BRIGHAM AND WOMEN'S HOSPITAL | Targeting Estrogen-Induced COX-2 Activity in Lymphangioliomyomatosis (LAM) | \$121,999.00 |
| 2011 | PERRIMON, NORBERT | HARVARD UNIVERSITY | Unbiased Combinatorial Genomic Approaches to Identify Alternative Therapeutic Targets within the TSC Signaling Network | \$998,375.00 |
| 2010 | BEAR, MARK | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | Role of Altered mGluR Activity in Cognitive Impairments in TSC: Implications for a Novel Method Treatment | \$698,510.00 |
| 2010 | NELSON, CHARLES | CHILDREN'S HOSPITAL, BOSTON | Defining Early Markers of Neurodevelopmental Disorders in Infants with TSC | \$1,490,090.00 |
| 2009 | BLÉNIS, JOHN | HARVARD UNIVERSITY | Identification of Genes and Compounds that Control the Viability of Cells Lacking Tsc2 | \$169,500.00 |
| 2009 | CHAN, JOANNE | CHILDRENS HOSPITAL | Neuronal VEGF Signaling Enhances Tsc1/2 Deficiency to Promote TSC Progression | \$171,583.00 |
| 2009 | GAN, BOYI | DANA-FARBER CANCER INSTITUTE | TSC-FoxO Signaling Network in Kidney Cancer Development | \$494,392.00 |
| 2009 | LADIAS, JOHN | BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON | Structural Basis for TSC1-TSC2 Complex Function | \$782,688.00 |
| 2009 | MANNING, BRENDAN | HARVARD UNIVERSITY | Defining the Therapeutic Implications of the Integrative Stress Response in TSC | \$726,750.00 |
| Massachusetts continued | | | | |
| 2009 | PAUL, ELAHNA | MASSACHUSETTS GENERAL HOSPITAL | Biomarkers of Renal Tumor Burden and Progression in TSC | \$176,998.00 |
| 2008 | YOSHII, AKIRA | MIT | Studying Protein Synthesis-Dependent Synaptic Changes in Tuberous Sclerosis | \$567,840.00 |
| 2006 | LADIAS, JOHN | BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON | Structural Basis for TSC1-TSC2 Complex Formation | \$113,900.00 |
| 2006 | LONG, XIAOMENG | MASSACHUSETTS GENERAL HOSPITAL | Screening for Chemical Compounds that Specifically Interfere with TSC-Rheb-TOR Signaling | \$117,206.00 |
| 2006 | SABATINI, DAVID M | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | Structural and Mechanistic Analyses of TSC1/2- and Rheb1/2-Mediated Regulation of the mTOR Pathway | \$779,922.00 |
| 2004 | SABATINI, DAVID M | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | Identifying Novel Drug Targets for the Treatment of Tuberous Sclerosis Complex Using High Throughput Technologies | \$100,000.00 |
| 2004 | SAHIN, MUSTAFA | CHILDREN'S HOSPITAL, BOSTON | Development of Peptide Inhibitors of Rheb Signaling Pathway | \$100,000.00 |
| 2003 | KAELIN, WILLIAM G | DANA-FARBER CANCER INSTITUTE | Hypoxia-Inducible Factor Regulation by the TSC2 Tumor Suppressor Protein | \$356,600.00 |
| 2003 | SABATINI, BERNARDO | HARVARD UNIVERSITY | The Role of TSC1 in the Formation and Maintenance of Excitatory Synapses | \$425,000.00 |
| 2002 | ITO, NAOTO | MASSACHUSETTS GENERAL HOSPITAL | Functions of TSC Genes in the Nervous System in Drosophila Melanogaster | \$420,569.00 |
| Michigan | | | | \$1,810,446.70 |
| 2024 | HOFFMANN, HANNE | MICHIGAN STATE UNIVERSITY | Light Therapy for TSC | \$221,043.00 |
| 2021 | DOMBKOWSKI, ALAN A | WAYNE STATE UNIVERSITY | Exosome Biomarkers of Epilepsy in Tuberous Sclerosis Complex Patients | \$223,998.00 |
| 2014 | INOKI, KEN | UNIVERSITY OF MICHIGAN | Mechanism of Ribosomes Biogenesis in TSC | \$845,679.00 |
| 2013 | DOMBKOWSKI, ALAN | WAYNE STATE UNIVERSITY | The Role of 5-Hydroxymethylcytosine in Gene Dysregulation of Epileptogenic Tubers in Tuberous Sclerosis Complex Patients | \$149,942.00 |
| 2006 | GUAN, KUN-LIANG | UNIVERSITY OF MICHIGAN | Regulation of the mTOR Pathway by a Novel Rheb Binding Protein BNIP3 | \$99,784.70 |
| 2005 | GUAN, KUN-LIANG | UNIVERSITY OF MICHIGAN | BIG1 as a Potential Guanine Nucleotide Exchange Factor for Rheb | \$100,000.00 |

Department of Defense Tuberous Sclerosis Complex Research Program Funded Grants FY2002-2025

| State/Country | PI | Institution | Project | Award Total |
|----------------------|------------------------|---|---|-----------------------|
| 2005 | GUAN, KUN-LIANG | UNIVERSITY OF MICHIGAN | Function of p53 in Regulation of TSC Mutant Cell Apoptosis | \$70,000.00 |
| 2004 | GUAN, KUN-LIANG | UNIVERSITY OF MICHIGAN | Regulation of TSC1/TSC2 Stability and Rheb GTP Level by Herc1 | \$100,000.00 |
| Minnesota | | | | \$2,822,567.00 |
| 2018 | KIM, DO-HYUNG | UNIVERSITY OF MINNESOTA | Role of the Immunoproteasome in TSC Pathogenesis and Therapeutics | \$693,000.00 |
| 2015 | YONG, JEONGSIK | UNIVERSITY OF MINNESOTA | Characterization of mTOR-Responsive Truncated mRNAs in Cell Proliferation | \$226,800.00 |
| 2012 | KIM, DO-HYUNG | UNIVERSITY OF MINNESOTA | Targeting Amino Acid-mTORC1 Signaling Limb for TSC Suppression | \$645,998.00 |
| 2005 | KIM, DO-HYUNG | UNIVERSITY OF MINNESOTA | Defining the Regulatory Mechanisms of Rheb-mTOR Signaling Activated in Tuberous Sclerosis Complex | \$100,000.00 |
| 2006 | KIM, DO-HYUNG | UNIVERSITY OF MINNESOTA | Functional Proteomics of TSC-mTOR Signaling | \$596,567.00 |
| 2006 | SELLECK, SCOTT | UNIVERSITY OF MINNESOTA | Understanding the Function of Tuberous Sclerosis Complex Genes in Neural Development: Roles in Synapse Assembly and Axon Guidance | \$560,202.00 |
| Missouri | | | | \$2,054,762.00 |
| 2021 | WONG, MICHAEL | WASHINGTON UNIVERSITY | Mechanisms of Sleep-Seizure Interactions in Tuberous Sclerosis Complex | \$781,381.00 |
| 2020 | WONG, MICHAEL | WASHINGTON UNIVERSITY | The Role of Blood-Brain Barrier Dysfunction in Epilepsy in TSC | \$236,250.00 |
| 2014 | WEBER, JASON | WASHINGTON UNIVERSITY | Identification of NPM and DDX5 as Therapeutic Targets in TSC | \$152,500.00 |
| 2011 | WONG, MICHAEL | WASHINGTON UNIVERSITY | The Role of Brain Inflammation in Epileptogenesis in TSC | \$152,000.00 |
| 2004 | SHIPLEY, JAMES M | WASHINGTON UNIVERSITY | Modeling Phenotypes of Tuberous Sclerosis in the Mouse | \$307,949.00 |
| 2002 | GUTMANN, DAVID | WASHINGTON UNIVERSITY | Mouse Models of TSC-Related Epilepsy | \$424,682.00 |
| New Jersey | | | | \$2,587,482.00 |
| 2022 | VALVEZAN, ALEXANDER | RUTGERS, NEW JERSEY, STATE UNIVERSITY OF | Defining the Cell Cycle Phase-Specific Regulation and Function of mTORC1 to Identify New Therapeutic Targets in TSC Tumors | \$783,077.00 |
| 2019 | VALVEZAN, ALEXANDER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | Defining Cellular Stresses Sensed Through the TSC Complex to Identify Vulnerabilities in TSC Tumors | \$234,750.00 |
| 2015 | D'ARCANGELO, GABRIELLA | RUTGERS UNIVERSITY, NEW BRUNSWICK | Cell Type-Specific Contributions to the TSC Neuropathology | \$816,171.00 |
| 2011 | D'ARCANGELO, GABRIELLA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | Exploring the Interaction between TSC2, PTEN, and the NMDA Receptor in Animal Models of Tuberous Sclerosis | \$155,000.00 |
| 2009 | WOOD, TERESA | NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF, ROBERT WOOD JOHNSON MEDICAL SCHOOL | TSC Regulates Oligodendroglial Differentiation and Myelination in the CNS | \$154,012.00 |
| 2004 | CHADA, KIRAN K | NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF, ROBERT WOOD JOHNSON MEDICAL SCHOOL | HMGA2 in Tuberous Sclerosis | \$444,472.00 |
| New Mexico | | | | \$761,506.00 |
| 2024 | SOLEIMANI, MANOOCHER | UNIVERSITY OF NEW MEXICO | Identification of Therapeutically Targetable Molecules and Pathways for the Treatment of Cystic Kidneys in Tuberous Sclerosis Complex | \$761,506.00 |
| New York | | | | \$9,648,739.00 |
| 2024 | TANG, GUOMEI | COLUMBIA UNIVERSITY MEDICAL CENTER | Restoring GABAergic Inhibition as a Potential Therapy for TSC-Associated Neurocognitive Impairment | \$822,501.00 |

Department of Defense Tuberous Sclerosis Complex Research Program Funded Grants FY2002-2025

| State/Country | PI | Institution | Project | Award Total |
|---------------------------|---------------------------|--|---|-----------------------|
| 2023 | HUANG, YUNFEI | ALBANY MEDICAL CENTER HOSPITAL | Transcellular mTOR Signaling Between Neurons and Microglia and Its Implications in TSC | \$815,000.00 |
| 2022 | HAMMES, STEPHEN R | UNIVERSITY OF ROCHESTER | Estrogen Promotes Lymphangiomiomatosis (LAM) Indirectly Through Stimulation of Innate Immunity | \$770,000.00 |
| 2021 | TANG, GUOMEI | COLUMBIA UNIVERSITY MEDICAL CENTER | Autophagy Induction as a Novel Therapeutic Strategy for TSC-Associated Cognitive and Autistic Social Deficits | \$810,000.00 |
| 2020 | D'ARMIENTO, JEANINE M | COLUMBIA UNIVERSITY MEDICAL CENTER | LAM Pilot Study with Nilotinib LAMP-2 | \$859,380.00 |
| 2020 | HOLZ, MARINA K | NEW YORK MEDICAL COLLEGE | KCC2 Dysfunction Enhances Synaptic Excitability of Cytomegalic Neurons in TSC | \$243,000.00 |
| 2017 | D'ARMIENTO, JEANINE MARIE | COLUMBIA UNIVERSITY MEDICAL CENTER | Neural Crest Origin of TSC Tumors | \$719,994.00 |
| 2016 | BLÉNIS, JOHN | JOAN & SANFORD I WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY | Metabolic Regulation of mTORC1 Catalytic Activity | \$762,750.00 |
| 2015 | TANG, GUOMEI | COLUMBIA UNIVERSITY MEDICAL CENTER | Impaired mTOR Macroautophagy and Neurocognitive Deficits in Tuberous Sclerosis Complex | \$720,000.00 |
| 2014 | GOLDMAN, JAMES E | COLUMBIA UNIVERSITY MEDICAL CENTER | Molecular Mechanisms Underlying the Epileptogenesis and Seizure Progression in Tuberous Sclerosis | \$679,999.00 |
| 2013 | QIAN, SHU-BING | CORNELL UNIVERSITY, ITHACA | Defining Translational Reprogramming in Tuberous Sclerosis Complex | \$658,750.00 |
| 2011 | SULZER, DAVID | COLUMBIA UNIVERSITY | Altered Astrocyte-Neuron Interactions and Epileptogenesis in Tuberous Sclerosis Complex Disorder | \$704,306.00 |
| 2011 | HAMMES, STEPHEN | UNIVERSITY OF ROCHESTER | Uterine-Specific Knockout of TSC-2: A Mouse Model for Lymphangiomiomatosis (LAM) | \$152,000.00 |
| New York continued | | | | |
| 2010 | QIAN, SHU-BING | CORNELL UNIVERSITY, ITHACA | Genome-Wide Analysis of Translational Control in Tuberous Sclerosis Complex | \$146,810.00 |
| 2008 | TSANG, STEPHEN | COLUMBIA UNIVERSITY | Preventing Visual Handicap in Children with Tuberous Sclerosis Complex | \$482,300.00 |
| 2006 | LEATHERWOOD, JANET | STATE UNIVERSITY OF NEW YORK AT STONY BROOK | A Search for New Therapeutic Targets: Using Yeast to Find the GEF for Rheb | \$101,949.00 |
| 2005 | JAFFREY, SAMIE R | WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY | Role of TSC1/2 in Axonal Development and Neuronal Morphogenesis | \$100,000.00 |
| 2004 | ZHONG, YI | COLD SPRING HARBOR LABORATORY | Analysis of Learning Disabilities of Tuberous Sclerosis Complex in Drosophila | \$100,000.00 |
| North Carolina | | | | \$2,716,351.00 |
| 2024 | WALSH, KYLE M | DUKE UNIVERSITY | Integrative Transcriptomic and Epigenomic Profiling of Subependymal Giant Cell Astrocytoma at Single-Cell Resolution | \$240,897.00 |
| 2022 | CAPAL, JAMIE K | NORTH CAROLINA AT CHAPEL HILL, UNIVERSITY OF | Regulating Together in Tuberous Sclerosis Complex: A Pilot Feasibility Study in Children and Adolescents with TSC-Associated Neuropsychiatric Disorder (TAND) | \$1,188,902.00 |
| 2018 | RAAB-GRAHAM, KIMBERLY F | WAKE FOREST UNIVERSITY HEALTH SCIENCES | Investigative Studies into mTORC1-Dependent Dendritic Branch Potentiation in TSC | \$652,954.00 |
| 2013 | ANTON, EVA | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | Disrupted Cilia Signaling in Tuberous Sclerosis Complex | \$633,598.00 |
| Ohio | | | | \$4,494,790.00 |
| 2024 | HESTER, MARK | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | Preclinical Development of Micro-Tuberin Gene Therapy for Tuberous Sclerosis Complex Type 2 | \$703,000.00 |

Department of Defense Tuberous Sclerosis Complex Research Program Funded Grants FY2002-2025

| State/Country | PI | Institution | Project | Award Total |
|-----------------------|-------------------------|--|---|-----------------------|
| 2023 | SHI, WEI | UNIVERSITY OF CINCINNATI | Characterization of Novel Perivascular Lesions Caused by Specific Deletion of Tsc2 in Hematopoietic Cells | \$243,000.00 |
| 2022 | RITTER, DAVID | CHILDREN'S HOSPITAL, CINCINNATI | Cardiac Rhabdomyomas as Biomarkers of TSC Disease Severity | \$213,281.00 |
| 2021 | DIFRANCESCO, MARK | CHILDREN'S HOSPITAL, CINCINNATI | Establishing Network Connectivity and Microvascular Imaging Biomarkers for Tuberous Sclerosis Complex | \$755,762.00 |
| 2021 | LETTERIO, JOHN | CASE WESTERN RESERVE UNIVERSITY | Development of Novel Synthetic Triterpenoids for the Chemoprevention of Neurological Manifestations of Tuberous Sclerosis Complex | \$241,500.00 |
| 2020 | HESTER, MARK | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | Dissecting Mechanisms Underlying Brain Calcification in TSC | \$231,000.00 |
| 2019 | YU, JANE J | UNIVERSITY OF CINCINNATI | Dysregulation of Sphingolipid Metabolism and Actions in Tuberous Sclerosis Complex | \$722,250.00 |
| 2018 | YU, JANE J | UNIVERSITY OF CINCINNATI | Development of Remission-Inducing Therapy for TSC Tumors | \$160,500.00 |
| 2010 | LI, YU | CHILDREN'S HOSPITAL, CINCINNATI | Noninvasive, MR-Guided HIFU Therapy of TSC-Associated Renal Angiomyolipomas | \$152,624.00 |
| 2009 | MCCORMACK, FRANCIS | UNIVERSITY OF CINCINNATI | LAMS Clinics Research Network | \$1,103,808.00 |
| 2005 | BISSLER, JOHN | CHILDREN'S HOSPITAL, CINCINNATI | Tuberous Sclerosis Complex Natural History Study: Renal Manifestations | \$814,065.00 |
| 2004 | XU, LI-HUI | ONCOIMMUNE, LTD. | Study of 2-Deoxyglucose as a Potential Treatment for TSC | \$100,000.00 |
| Pennsylvania | | | | \$2,214,061.00 |
| 2021 | OBRAZTSOVA, KSENIYA | PENNSYLVANIA, UNIVERSITY OF | Defining Molecular Mechanism for Targeting the Female-Specific TSC-LAM | \$243,750.00 |
| 2015 | STEPANOVA, VICTORIA | UNIVERSITY OF PENNSYLVANIA | Role of Urokinase-Type Plasminogen Activator (uPA) in Progression of TSC Tumors | \$240,000.00 |
| 2008 | ASTRINIDIS, ARISTOTELIS | DREXEL UNIVERSITY SCHOOL OF MEDICINE | Role of the Hamartin-Plk1 Interaction in Tuberous Sclerosis Complex Pathogenesis | \$675,000.00 |
| 2005 | CRINO, PETER B | UNIVERSITY OF PENNSYLVANIA | Mutational Analysis of Cell Types in Tuberous Sclerosis Complex (TSC) | \$406,560.00 |
| 2005 | LIU, YONG-JIAN | UNIVERSITY OF PITTSBURGH | Molecular Mechanisms of Neurological Disorders in TSC | \$100,000.00 |
| 2003 | KRYMSKAYA, VERA P | UNIVERSITY OF PENNSYLVANIA | The Role of TSC Proteins in Regulating Cell Adhesion and Motility | \$150,000.00 |
| 2002 | HENSKE, ELIZABETH | FOX CHASE CANCER CENTER | TSC1 and TSC2 Gene Homologs in Schizosaccharomyces Pombe | \$398,751.00 |
| Rhode Island | | | | \$869,815.00 |
| 2011 | ZERVAS, MARK | BROWN UNIVERSITY | Temporal Loss of Tsc1: Neural Development and Brain Disease in Tuberous Sclerosis | \$716,530.00 |
| 2010 | ZERVAS, MARK | BROWN UNIVERSITY | Determining Neuronal Circuits in Tuberous Sclerosis | \$153,285.00 |
| South Carolina | | | | \$924,765.00 |
| 2019 | FELICIANO, DAVID M | CLEMSON UNIVERSITY | A Subependymal Giant Cell Astrocytoma (SEGA) Mouse Model | \$667,968.00 |
| 2013 | STRANGE, CHARLIE | MEDICAL UNIVERSITY OF SOUTH CAROLINA | LAM Pilot Study with Imatinib Mesylate (LAMP-1) | \$256,797.00 |
| Tennessee | | | | \$4,055,037.00 |
| 2022 | CHAUM, EDWARD | VANDERBILT UNIVERSITY MEDICAL CENTER | Optimizing Therapeutic Control of Epilepsy in Tuberous Sclerosis Complex Using a Novel Biosensor | \$1,567,533.00 |
| 2017 | ZAREI, MAHSA | VANDERBILT UNIVERSITY | Targeting Transcriptional Addiction for the Treatment of TSC | \$222,751.00 |
| 2015 | IHRIE, REBECCA A | VANDERBILT UNIVERSITY | Identifying Novel Candidate Therapies for SEGAs Using Quantitative Single-Cell Assays | \$930,096.00 |

Department of Defense Tuberous Sclerosis Complex Research Program Funded Grants FY2002-2025

| State/Country | PI | Institution | Project | Award Total |
|----------------------|-------------------------|---|---|-----------------------|
| 2013 | BISSLER, JOHN | UNIVERSITY OF TENNESSEE, HEALTH SCIENCE CENTER | Prevention of TSC Renal Disease | \$637,501.00 |
| 2009 | ESS, KEVIN | VANDERBILT UNIVERSITY | Neural Development in tsc2-Deficient Zebrafish | \$697,156.00 |
| Texas | | | | \$8,863,065.58 |
| 2024 | RICHARD, MELISSA | BAYLOR COLLEGE OF MEDICINE | The Clinical and Genetic Architecture of Autism Spectrum Disorder Among Individuals With Tuberous Sclerosis Complex | \$614,936.00 |
| 2023 | HAMILTON, LIBERTY | UNIVERSITY OF TEXAS AT AUSTIN | Brain Representations of Language in Children with Tuberous Sclerosis Complex | \$628,677.00 |
| 2023 | WEINER, HOWARD | BAYLOR COLLEGE OF MEDICINE | Brain Representations of Language in Children with Tuberous Sclerosis Complex | \$1,171,770.00 |
| 2021 | BRAGER, DARRIN | UNIVERSITY OF TEXAS AT AUSTIN | Voltage-Gated Ion Channel Dysfunction in Tuberous Sclerosis | \$231,237.00 |
| 2020 | ANDERSON, ANNE | BAYLOR COLLEGE OF MEDICINE | Mechanisms of Epileptogenesis and Circuit Dysfunction in a Mouse Model of TSC | \$722,250.00 |
| 2018 | PENG, GUANG | M.D. ANDERSON CANCER CENTER, UNIVERSITY OF TEXAS | Maintenance of Genome Stability in TSC2-Deficient Tumors | \$160,000.00 |
| 2018 | JIANG, XIAOLONG | BAYLOR COLLEGE OF MEDICINE | Deciphering Circuit-Level Mechanisms Underlying Intrinsic Epileptogenicity of Cortical Tubers in TSC | \$160,072.00 |
| 2017 | FARACH, LAURA | UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON | Developing a Genetic Risk Prediction Model for Epilepsy in Patients with TSC | \$627,069.00 |
| 2016 | TSAI, PETER | TEXAS, UNIVERSITY OF, SOUTHWESTERN MEDICAL CENTER AT DALLAS | Neural Circuits Underlying Autism-Relevant Behaviors in TSC | \$708,784.00 |
| 2014 | KARBOWNICZEK, MAGDALENA | TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER, LUBBOCK | Identifying Mechanisms Initiating LAM and Angiomyolipoma in Tuberous Sclerosis Complex | \$641,746.00 |
| 2013 | RAAB-GRAHAM, KIMBERLY | UNIVERSITY OF TEXAS AT AUSTIN | Molecular Studies Investigating the Link Between Dendritic mRNA Translation and Repression Leading to Epilepsy in TSC | \$800,064.00 |
| 2010 | GAMBELLO, MICHAEL | UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON | Behavioral Analysis and Rescue of a Novel Cerebellar Mouse Model of Tuberous Sclerosis Complex | \$149,643.00 |
| 2010 | KOENIG, MARY K | UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON | Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex | \$1,798,869.00 |
| 2009 | WALKER, CHERYL | M.D. ANDERSON CANCER CENTER, UNIVERSITY OF TEXAS | TSC2 and Cystogenesis | \$111,382.00 |
| 2006 | GAMBELLO, MICHAEL | UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON | Targeted Disruption of Tsc2 Gene in the Mouse Cerebellum | \$95,259.58 |
| 2005 | WALKER, CHERYL | M.D. ANDERSON CANCER CENTER, UNIVERSITY OF TEXAS | TSC2 Haploinsufficiency Leads to a Mutator Phenotype | \$100,000.00 |
| 2004 | SPARAGANA, STEVEN P | TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN | Tuberous Sclerosis Complex National Database | \$141,307.00 |
| Vermont | | | | \$155,661.17 |
| 2018 | MAHONEY, JOHN M | UNIVERSITY OF VERMONT & STATE AGRICULTURAL COLLEGE | Systems Genetics of Tuberous Sclerosis Complex Outcomes Using BXD Recombinant Inbred Mice | \$155,661.17 |
| Virginia | | | | \$238,794.00 |
| 2022 | WENKER, IAN | VIRGINIA, UNIVERSITY OF | Mechanisms of Seizure-Induced Death of TSC Model Mice | \$238,794.00 |
| Washington | | | | \$232,295.00 |
| 2012 | XU, WENQUING | UNIVERSITY OF WASHINGTON | 3D Structure of TSC1 | \$154,295.00 |
| 2008 | XU, WENQUING | UNIVERSITY OF WASHINGTON | Structural Studies of the HERC1-Tuberin Interaction | \$78,000.00 |
| West Virginia | | | | \$84,420.00 |
| 2006 | GUO, HUI-FU | WEST VIRGINIA UNIVERSITY | Analyzing the Functions of Tuberous Sclerosis Complex in Synapse Development and Synaptic Plasticity in Drosophila | \$84,420.00 |

Department of Defense Tuberous Sclerosis Complex Research Program Funded Grants FY2002-2025

| State/Country | PI | Institution | Project | Award Total |
|------------------------|---------------------|---|--|-----------------------|
| Wisconsin | | | | \$144,211.00 |
| 2013 | HORNBERGER, TROY A | UNIVERSITY OF WISCONSIN, MADISON | The Role of TSC2 Phosphorylation in the Regulation of TSC2 Localization and mTOR Signaling | \$144,211.00 |
| Australia | | | | \$754,255.00 |
| 2018 | ELLISDON, ANDREW M | MONASH UNIVERSITY | Structural Basis of Tuberous Sclerosis Complex Assembly and Dysregulation in Disease | \$754,255.00 |
| Belgium | | | | \$663,190.00 |
| 2023 | JANSEN, ANNA | VRIJE UNIVERSITEIT BRUSSEL | TANDem 2: Closing the Gap to Interventions for TAND | \$663,190.00 |
| Canada | | | | \$1,317,216.00 |
| 2013 | KARAGIANNIS, JIM | UNIVERSITY OF WESTERN ONTARIO | Using Genetic Buffering Relationships Identified in Fission Yeast to Elucidate the Molecular Pathology of Tuberous Sclerosis | \$84,318.00 |
| 2013 | STANFORD, WILLIAM | UNIVERSITY OF OTTAWA | Modeling TSC and LAM Using Patient-Derived Induced Pluripotent Stem Cells | \$658,419.00 |
| 2010 | ROBERGE, MICHEL | UNIVERSITY OF BRITISH COLUMBIA | Study of mTOR Signaling Inhibitors as Potential Treatment for TSC | \$107,050.00 |
| 2008 | STAMBOLIC, VUK | UNIVERSITY HEALTH NETWORK, TORONTO | Development of a Novel NMR-Based Rheb GTPase Assay and Molecular Characterization of TSC2 GAP Activity | \$110,400.00 |
| 2005 | MCNEILL, HELEN | MOUNT SINAI HOSPITAL, SAMUEL LUNENFELD RESEARCH INSTITUTE | Genetic and Molecular Analysis of the Mechanisms by which TSC Regulates Neuronal Differentiation | \$357,029.00 |
| England | | | | \$584,708.00 |
| 2018 | DUNLOP, ELAINE | CARDIFF UNIVERSITY | An Innovative Model System of Cell Invasion in TSC/LAM to Uncover New Drug Targets and Therapies | \$99,995.00 |
| 2016 | BATEMAN, JOSEPH | KING'S COLLEGE, LONDON | Establishing the Molecular Basis of the Neurodevelopmental Features of TSC | \$484,713.00 |
| Germany | | | | \$146,049.35 |
| 2019 | KUEMMEL, DANIEL | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER | Structural Analysis of the TSC Complex by Single Particle Reconstruction | \$146,049.35 |
| Japan | | | | \$420,000.00 |
| 2004 | MATSUMOTO, TOMOHIRO | KYOTO UNIVERSITY | Fission Yeast Model Study for Dissection of TSC Pathway | \$420,000.00 |
| Switzerland | | | | \$714,141.00 |
| 2021 | HALL, MICHAEL N | UNIVERSITAT BASEL | Selective mTORC1 Inhibitors to Treat TSC | \$549,471.00 |
| 2019 | HALL, MICHAEL N | UNIVERSITAT BASEL | Novel mTORC1 Inhibitors to Treat TSC | \$164,670.00 |
| The Netherlands | | | | \$350,548.00 |
| 2006 | NELLIST, MARK | Erasmus MC-Daniel den Hoed Cancer Center | Biochemical Characterization of TSC1 and TSC2 Variants Identified in Patients with Tuberous Sclerosis Complex | \$350,548.00 |